Cliff Asness's CPRX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 337,052 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $6.64 M, representing 0.00% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in CPRX, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 968,574 shares. Largest reduction occurred in Q2 2018, reducing 427,301 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +149,682 | New Buy | 149,682 | $1.95 |
| Q1 2014 | +51,600 | Add 34.47% | 201,282 | $2.26 |
| Q2 2014 | +39,000 | Add 19.38% | 240,282 | $2.53 |
| Q4 2014 | -29,400 | Reduce 12.24% | 210,882 | $2.97 |
| Q1 2015 | -26,100 | Reduce 12.38% | 184,782 | $4.33 |
| Q3 2015 | -45,220 | Reduce 24.47% | 139,562 | $3.00 |
| Q4 2015 | -75,820 | Reduce 54.33% | 63,742 | $2.45 |
| Q1 2016 | -63,742 | Sold Out | 63,742 | $0.00 |
| Q3 2017 | +352,626 | New Buy | 352,626 | $2.52 |
| Q4 2017 | -16,048 | Reduce 4.55% | 336,578 | $3.91 |
| Q1 2018 | +466,119 | Add 138.49% | 802,697 | $2.39 |
| Q2 2018 | -427,301 | Reduce 53.23% | 375,396 | $3.12 |
| Q3 2018 | -176,800 | Reduce 47.10% | 198,596 | $3.78 |
| Q4 2018 | -58,754 | Reduce 29.58% | 139,842 | $1.92 |
| Q1 2019 | -77,245 | Reduce 55.24% | 62,597 | $5.10 |
| Q2 2019 | +217,841 | Add 348.01% | 280,438 | $3.84 |
| Q3 2019 | -113,868 | Reduce 40.60% | 166,570 | $5.31 |
| Q4 2019 | +968,574 | Add 581.48% | 1.14 M | $3.75 |
| Q1 2020 | +77,305 | Add 6.81% | 1.21 M | $3.85 |
| Q2 2020 | -307,205 | Reduce 25.34% | 905,244 | $4.62 |
| Q3 2020 | -55,712 | Reduce 6.15% | 849,532 | $2.97 |
| Q4 2020 | +143,899 | Add 16.94% | 993,431 | $3.34 |
| Q1 2021 | -269,778 | Reduce 27.16% | 723,653 | $4.61 |
| Q2 2021 | -399,455 | Reduce 55.20% | 324,198 | $5.75 |
| Q3 2021 | +151,119 | Add 46.61% | 475,317 | $5.30 |
| Q4 2021 | -37,244 | Reduce 7.84% | 438,073 | $6.77 |
| Q1 2022 | -24,521 | Reduce 5.60% | 413,552 | $8.29 |
| Q2 2022 | +73,989 | Add 17.89% | 487,541 | $7.01 |
| Q3 2022 | -86,910 | Reduce 17.83% | 400,631 | $12.83 |
| Q4 2022 | -172,201 | Reduce 42.98% | 228,430 | $18.60 |
| Q1 2023 | +35,794 | Add 15.67% | 264,224 | $16.58 |
| Q2 2023 | +378,770 | Add 143.35% | 642,994 | $13.44 |
| Q3 2023 | -166,194 | Reduce 25.85% | 476,800 | $11.69 |
| Q4 2023 | -133,999 | Reduce 28.10% | 342,801 | $16.81 |
| Q1 2024 | -81,736 | Reduce 23.84% | 261,065 | $15.94 |
| Q2 2024 | +227,321 | Add 87.07% | 488,386 | $15.49 |
| Q3 2024 | -29,034 | Reduce 5.94% | 459,352 | $19.88 |
| Q4 2024 | +17,659 | Add 3.84% | 477,011 | $20.87 |
| Q1 2025 | -31,501 | Reduce 6.60% | 445,510 | $24.25 |
| Q2 2025 | -47,088 | Reduce 10.57% | 398,422 | $21.70 |
| Q3 2025 | -61,370 | Reduce 15.40% | 337,052 | $19.70 |
Cliff Asness's Catalyst Pharmaceuticals Investment FAQs
Cliff Asness first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q4 2013, acquiring 149,682 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Catalyst Pharmaceuticals, Inc. (CPRX) for 48 quarters since Q4 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q4 2019, adding 1,135,144 shares worth $4.26 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 337,052 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $6.64 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 1,212,449 shares, as reported at the end of Q1 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.